Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0010200 (cough)
 23,843 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Pulmonary endothelium takes part in the metabolization of some products such as prostaglandins, norepinefrine, serotonin, bradikinin and angiotensin I. Angiotensin I is the substrate for Angiotensin Converting Enzyme (ACE). It is known that greatest production site of ACE is the pulmonary endothelium. A lot of studies have been done for determining the levels of ACE in various lung diseases. It has been observed that serum ACE activity is increased in granulomatous diseases such as sarcoidosis and berylliosis. In patients with bronchial carcinoma, serum ACE activity is found to be decreased. There are some papers about the significant changes in serum ACE activities in asthmatic patients. We determined the activity of ACE and total IgE levels at the serum of 40 asthmatic patients and 20 healthy subjects. Among 40 patients 20 of them were mild asthmatic and they developed symptoms only during the attacks. The remainder 20 patients were chronic asthmatics and all the time they had the symptoms of dyspnea, wheezing and coughing. Serum ACE activity was found 25.5 +/- 11.77 U in the control group, 22.8 +/- 8.04 U in mild asthmatic group and 16.6 +/- 6.13 U in chronic asthmatic group. When compared with control group serum ACE levels found to be significantly decreased in chronic asthmatic group. Also a weak but significant correlation was found between serum total IgE levels and ACE activity in the chronic asthmatic group. These findings suggest that there is a relation between ACE and Total IgE production.
 ...
PMID:The relationship between serum ACE activity and total IgE levels in patients with bronchial asthma. 1038 31

Angiotensin II(AII) accelerates the progress of cardiovascular diseases. This was proved by the fact that the blockade of renin-angiotensin system provided clinical benefits for patients with cardiovascular diseases. This review focuses on the differences between AT1-receptor antagonist and ACE inhibitor in basic and clinical aspects. Beside decreased AII concentration, increased tissue bradykinin concentration may contribute to the beneficial effect of ACE inhibitor, on the other hand, this increases the rate of cough to decrease the compliance. Increased AII concentration by AII receptor antagonist may antagonize the binding of the drug as well as stimulate AT2 receptor subtype. ACE inhibitor can not block the effect of non-ACE AII formation, but AII receptor does. These differences should be considered for their clinical use.
 ...
PMID:[Comparison between AngII receptor antagonist and ACE inhibitor]. 1139 5